Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2026 | $42.00 | Outperform | Wolfe Research |
| 3/9/2026 | $52.00 | Outperform | RBC Capital Mkts |
| 10/15/2025 | $60.00 | Buy | H.C. Wainwright |
| 10/9/2025 | $27.00 | Underperform → Neutral | BofA Securities |
| 6/11/2025 | $32.00 | Buy | Guggenheim |
| 4/29/2025 | $28.00 | Overweight | Cantor Fitzgerald |
| 9/25/2023 | $27.00 | Outperform | Wedbush |
| 8/15/2023 | $10.00 → $34.00 | Equal-Weight → Overweight | Morgan Stanley |
Wolfe Research initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $42.00
RBC Capital Mkts initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $52.00
H.C. Wainwright initiated coverage of Pharvaris N.V. with a rating of Buy and set a new price target of $60.00
4 - Pharvaris N.V. (0001830487) (Issuer)
4 - Pharvaris N.V. (0001830487) (Issuer)
4 - Pharvaris N.V. (0001830487) (Issuer)
144 - Pharvaris N.V. (0001830487) (Subject)
144 - Pharvaris N.V. (0001830487) (Subject)
SCHEDULE 13G/A - Pharvaris N.V. (0001830487) (Subject)
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey. Details of the presentations are as follows: Title: Oral Deucrictibant Im
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks remains on-track in 1H2026Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacksCash and cash equivalents of €247 million as of March 31, 2026; subsequent closing of $132 million underwritten offering extends cash runway into 2028 ZUG, Switzerland, May 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonis
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema ("HAE") and acquired angioedema due to C1 inhibitor deficiency ("AAE-C1INH"), today announced the closing of its previously announced underwritten offering of 4,455,863 ordinary shares (which includes the exercise in full by the underwriters of their option to purchase up to an additional 581,199 ordinary shares). The gross proceeds to Pharvaris from the offering, before deducting underwriting di
NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
SC 13G/A - Pharvaris N.V. (0001830487) (Subject)
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and complete symptom resolution (median 11.95 hours)Well-tolerated safety profile of deucrictibant confirmedEfficacy and safety outcomes consistent across all HAE subtypes represented (HAE type 1, HAE type 2, and HAE with normal C1 inhibitor) and varying attack severities and locationsPharvaris to host a conference call and webcast today at 8:00 a.m. EST ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutica
CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece
Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi